Cleveland, OH, April 16, 2020. Haima Therapeutics (“Haima”) has been awarded a $750,000 Phase II Small Business Innovation Research (SBIR) grant from the National Science Foundation (NSF) to support the development of SynthoPlate, a platelet-inspired, IV-injectable hemostatic technology to mitigate bleeding in patients with bleeding dysfunctions such as non-compressible hemorrhage after traumatic injury, bleeding complica